CLINICAL RELEVANCE OF HIGH SENSITIVITY C-REACTIVE PROTEIN IN ACUTE MYOCARDIAL INFARCTION PATIENTS

KAMALDEEP KAUR; DEEP INDER SINGH; AMITA

doi:10.22159/ajpcr.2024.v17i5.50981

Authors

KAMALDEEP KAUR Department of Medicine, Government Medical College, Patiala, Punjab, India
DEEP INDER SINGH Department of Medicine, Mata Kaushalya Hospital, Patiala, Punjab, India. https://orcid.org/0009-0000-8671-4984
AMITA Department of Medicine, Government Medical College, Patiala, Punjab, India

DOI:

https://doi.org/10.22159/ajpcr.2024.v17i5.50981

Keywords:

Diabetes mellitus,, High-sensitivity C-reactive protein, Acute myocardial infarction, Inflammation.

Abstract

Objectives: Poor cardiovascular outcomes have been linked to high-sensitivity C-reaction protein (hs-CRP), a biomarker of residual inflammatory risk. Whether or not a patient has diabetes mellitus, evaluate the relationship among hs-CRP levels estimated at hospital admission and in-hospital consequences and death.

Methods: This prospective cohort study included 100 acute myocardial infarction (AMI) patients with both non-ST elevation myocardial infarction (STEMI) and STEMI who were admitted to the cardiac care critical care unit intensive therapy unit.

Results: Diabetics had a considerably higher incidence of hypertension (p=0.001) and dyslipidemia (p=0.001) compared to non-diabetics. Diabetics exhibited a significantly higher mean hs-CRP level (6.76±1.12 vs. 3.65±0.98 mg/dL; p=0.01) than non-diabetics. Meanwhile, compared to non-diabetics, diabetics utilized significantly more aspirin (p=0.001), beta-blockers (p=0.001), angiotensin receptor blockers (ARBs) (p=0.01), and statins (p=0.001). Furthermore, compared to those with hs-CRP <3 mg/L, those with hs-CRP ≥3 mg/dL had a significantly higher incidence of dyslipidemia (p=0.001) and hypertension (p=0.001).

Conclusion: The results of the current study demonstrated that hs-CRP upon admission is a valid predictor of hospital morbidity and death in patients with AMI who are diabetic or non-diabetic. Individuals with diabetes showed greater CRP levels than non-diabetic AMI patients did.

Downloads

Download data is not yet available.

References

Li Z, Lin L, Wu H, Yan L, Wang H, Yang H, et al. Global, regional, and national death, and disability-adjusted life-years (DALYs) for cardiovascular disease in 2017 and trends and risk analysis from 1990 to 2017 using the global burden of disease study and implicationsfor prevention. Front Public Health. 2021;9:559751. doi: 10.3389/ fpubh.2021.559751, PMID 34778156

Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010, PMID 33309175

Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke Statistics-2020 update: A report from the American Heart Association. Circulation. 2020;141(9):e139-596. doi: 10.1161/CIR.0000000000000757, PMID 31992061

Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke Statistics-2022 update: A report from the American Heart Association. Circulation. 2022;145(8):e153-639. doi: 10.1161/CIR.0000000000001052, PMID 35078371

Marenzi G, Cosentino N, Genovese S, Campodonico J, De Metrio M, Rondinelli M, et al. Reduced cardio-renal function accounts for most of the in-hospital morbidity and mortality risk among patients with type 2 diabetes undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Diabetes Care. 2019;42(7):1305-11. doi: 10.2337/dc19-0047, PMID 31048409

La Sala L, Prattichizzo F, Ceriello A. The link between diabetes and atherosclerosis. Eur J Prev Cardiol. 2019;26(2_suppl):15-24. doi: 10.1177/2047487319878373, PMID 31722564

Heo JM, Park JH, Kim JH, You SH, Kim JS, Ahn CM, et al. Comparison of inflammatory markers between diabetic and nondiabetic ST segment elevation myocardial infarction. J Cardiol. 2012;60(3):204-9. doi: 10.1016/j.jjcc.2012.03.006, PMID 22658696

Odegaard AO, Jacobs DR Jr., Sanchez OA, Goff DC Jr., Reiner AP, Gross MD. Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes. Cardiovasc Diabetol. 2016;15:51. doi: 10.1186/s12933-016-0369-6, PMID 27013319

Libby P. Inflammation during the life cycle of the atherosclerotic plaque. Cardiovasc Res. 2021;117(13):2525-36. doi: 10.1093/cvr/ cvab303, PMID 34550337

Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94(12):1543-53. doi: 10.1161/01.RES.0000130526.20854.fa, PMID 15217919

Biasucci LM, Koenig W, Mair J, Mueller C, Plebani M, Lindahl B, et al. How to use C-reactive protein in acute coronary care. Eur Heart J. 2013;34(48):3687-90. doi: 10.1093/eurheartj/eht435, PMID 24204013

Kushner I, Broder ML, Karp D. Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. J Clin Invest. 1978;61(2):235-42. doi: 10.1172/JCI108932, PMID 621273

Crea F, Libby P. Acute coronary syndromes: The way forward from mechanisms to precision treatment. Circulation. 2017;136(12):1155-66. doi: 10.1161/CIRCULATIONAHA.117.029870, PMID 28923905

Fu EL, Franko MA, Obergfell A, Dekker FW, Gabrielsen A, Jernberg T, et al. High-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post-myocardial infarction patients. Am Heart J. 2019;216:20-9. doi: 10.1016/j.ahj.2019.06.019, PMID 31382219

Mani P, Puri R, Schwartz GG, Nissen SE, Shao M, Kastelein JJ, et al. Association of initial and serial C-reactive protein levels with adverse cardiovascular events and death after acute coronary syndrome: A secondary analysis of the VISTA-16 trial. JAMA Cardiol. 2019;4(4):314-20. doi: 10.1001/jamacardio.2019.0179, PMID 30840024

Mascitelli L, Goldstein MR, Zacharski LR. Comment on Podmore et al. Association of multiple biomarkers of iron metabolism and type 2 diabetes: The EPIC-InterAct study. Diabetes Care 2016;39:572- 581. Diabetes Care. 2016;39(9):e149-50. doi: 10.2337/dc16-0538, PMID 27555627

Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, et al. A tale of two trials: A comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation. 2006;113(11):1406-14. doi: 10.1161/ CIRCULATIONAHA.105.586347, PMID 16534008

Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J. 2002;23(11):831-4. doi: 10.1053/euhj.2001.3052, PMID 12042000

Pitsavos C, Tampourlou M, Panagiotakos DB, Skoumas Y, Chrysohoou C, Nomikos T, et al. Association between low-grade systemic inflammation and type 2 diabetes mellitus among men and women from the Attica Study. Rev Diabet Stud. 2007;4(2):98-104. doi: 10.1900/RDS.2007.4.98, PMID 17823694

Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-43. doi: 10.1161/hc0902.104353, PMID 11877368

Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351(25):2599-610. doi: 10.1056/ NEJMoa040967, PMID 15602020

Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol. 2006;47(5):962-8. doi: 10.1016/j.jacc.2005.10.055, PMID 16516078

Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: A secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319-28. doi: 10.1016/S0140-6736(17)32814-3, PMID 29146124

Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo- Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;5(4):444-70. doi: 10.4239/wjd.v5.i4.444, PMID 25126392

Marenzi G, Cosentino N, Milazzo V, De Metrio M, Cecere M, Mosca S, et al. Prognostic value of the acute-to-chronic glycemic ratio at admission in acute myocardial infarction: A prospective study. Diabetes Care. 2018;41(4):847-53. doi: 10.2337/dc17-1732, PMID 29382659

Milazzo V, Cosentino N, Genovese S, Campodonico J, Mazza M, De Metrio M, et al. Diabetes mellitus and acute myocardial infarction: Impact on short and long-term mortality. Adv Exp Med Biol. 2021;1307:153-69. doi: 10.1007/5584_2020_481, PMID 32020518

MONICA/KORA Myocardial Infarction Registry, Meisinger C, HeierM, von Scheidt W, Kuch B. Admission C-reactive protein and short-as well as long-term mortality in diabetic versus non-diabetic patients with incident myocardial infarction. Clin Res Cardiol. 2010;99(12):817-23. doi: 10.1007/s00392-010-0193-z, PMID 20596713

Otter W, Winter M, Doering W, Standl E, Schnell O. C-reactive protein in diabetic and nondiabetic patients with acute myocardial infarction. Diabetes Care. 2007;30(12):3080-2. doi: 10.2337/dc07-1020, PMID 17848613

Xia M, Zhang C, Gu J, Chen J, Wang LC, Lu Y, et al. Impact of C-reactive protein on long-term mortality in acute myocardial infarction patients with diabetes and those without. Clin Chim Acta. 2018;480:220-4. doi: 10.1016/j.cca.2018.02.025, PMID 29476733